Skip to main content
NYRADA INC. logo

NYRADA INC. — Investor Relations & Filings

Ticker · NYR ISIN · AU0000070195 ASX Professional, scientific and technical activities
Open in API
Filings indexed 472 across all filing types
Latest filing 2024-02-27 Regulatory Filings
Country AU Australia
Listing ASX NYR

About NYRADA INC.

https://www.nyrada.com

Nyrada Inc. specializes in the development of novel small molecule therapeutic agents designed to address unmet needs in cardiovascular health and neuroprotection. The company’s lead programs include a cholesterol-lowering treatment and a neuroprotective treatment for brain injury. The cardiovascular program focuses on an oral PCSK9 inhibitor aimed at managing low-density lipoprotein (LDL) cholesterol levels as an alternative to injectable biologics. The neuroprotection program involves the development of NYR-BI03, a first-in-class small molecule designed to mitigate secondary brain damage following a stroke or traumatic brain injury by targeting canonical transient receptor potential (TRPC) ion channels. These efforts aim to provide effective, accessible pharmacological interventions for both chronic metabolic conditions and acute neurological trauma.

Recent filings

Filing Released Lang Actions
Significant Neuroprotection in NYR Preclinical Brain Injury 5 pages 377.9KB
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Nyrada Inc. about positive results from a preclinical study of their drug candidate NYR-BI03 for brain injury. It includes scientific data, study methodology, and future plans for clinical trials. The content focuses on research results and development updates rather than financial performance or regulatory compliance. It is not an annual or interim financial report, audit report, earnings release, or any regulatory filing. It is also not a presentation or transcript of a call. The document is a corporate announcement of scientific and development progress, which fits best under the category of a general Regulatory Filing (RNS) as it does not fit other specific categories and is a formal public disclosure of material company information.
2024-02-27 English
Appendix 4D and Half Year Report to 31 December 2023 19 pages 948.2KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Nyrada Inc. Appendix 4D Half-year report' and covers the half-year ended 31 December 2023. It includes detailed financial results, directors' report, auditor's review report, consolidated financial statements, and notes. The content includes comprehensive financial data and analysis for a period shorter than a full fiscal year, consistent with an interim or quarterly report. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement or certification. The presence of an auditor's review report and detailed financial statements confirms it is a substantive interim financial report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2024-02-19 English
Nyrada Half Year Results FY2024 4 pages 296.4KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Nyrada Half Year FY2024 Results' and provides detailed financial and operational updates for the half year ended 31 December 2023. It includes financial figures such as cash position, operating profit, and R&D costs, as well as substantive discussion of business programs and outlook. The length is 9097 characters, which is sufficient to contain detailed financial data and analysis. The content is consistent with a comprehensive interim or quarterly financial report rather than a brief announcement or presentation. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2024-02-19 English
Amended and Restated Certificate of Incorporation and Bylaws 29 pages 1.3MB
Regulatory Filings
2024-01-18 English
Quarterly Activities Report and Appendix 4C 9 pages 502.5KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Nyrada Quarterly Activities Report & Appendix 4C' and is dated 17 January 2024. It provides detailed updates on the company's activities, including progress on drug development programs, financial position, and cash flow statements for the quarter ending 31 December 2023. The inclusion of the Appendix 4C, which is a quarterly cash flow report required by the ASX Listing Rules, confirms this is a quarterly report. The document contains substantive financial data such as cash flows from operating, investing, and financing activities, cash balances, and payments to related parties. It is not merely an announcement or a brief summary but a comprehensive report for a period shorter than a full fiscal year. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2024-01-16 English
Nyrada Receives A$3.54M R&D Tax Incentive Rebate 2 pages 230.9KB
Capital/Financing Update Classification · 95% confidence The document is a short announcement dated 8 December 2023 from Nyrada Inc regarding receipt of a A$3.54 million R&D tax incentive rebate from the Australian Federal Government. It references the company's financial position and cash held as of 30 September 2023, but does not contain any detailed financial statements or substantive financial data. The document is only 3550 characters long, which is relatively short and consistent with a brief announcement rather than a full report. It does not present a full annual or quarterly report, nor does it include detailed management discussion or audit information. The content is focused on a specific financial update related to government rebate receipt, which is a capital/financing update type of information. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2023-12-07 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.